surpass cvot tirzepatide C. Michael Gibson MD on X: "SURPASS-CVOT trial: was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. # SURPASS-CVOT shows tirzepatide delivers comparable

Synthesis and perspectives Given the high prevalence, strong association with cardiometabolic disease, risk of progression to advanced liver disease, and growing burden alongside rising obesity and diabetes rates, MASLD represents a critical target for early identification, risk stratification, and integrated lifestyle and pharmacologic intervention

Compare that to the 25% lean mass loss seen in clinical trials without these interventions

Andrew Huberman That still seems high

Functional assessments: Observing improvements in mobility, strength, or recovery times in appropriate models

H., Gerostamoulos, J., Batziris, H., Chu, M., Caplehorn, J., Robertson, M